Search Within

Mohammad Atiq

Formats
  1. Meeting Abstract (10)
  2. Journal Article (6)
Groups
  1. Department of Medicine (14)
  2. Genitourinary Oncology Service (14)
  3. Sloan Kettering Institute Postdocs (14)
  4. Solid Tumor Oncology Division (14)
  5. GSK Faculty (3)
  6. Human Oncology and Pathogenesis Program (2)

More Groups

People
  1. Goutam Chakraborty (14)
  2. Philip Kantoff (14)
  3. Ying Mazzu (14)
  4. Yuki Yoshikawa (13)
  5. Nabeela Khan (10)
  6. Joshua Armenia (9)

More People

Years
  1. 2021 (1)
  2. 2020 (3)
  3. 2019 (5)
  4. 2018 (7)
Publications
  1. Journal of Clinical Oncology (6)
  2. Cancer Research (4)
  3. Clinical Cancer Research (3)
  4. Cureus (1)
  5. Molecular Oncology (1)
  6. The American Journal of Case Reports (1)
Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (6)
  3. Cureus Inc. (1)
  4. FEBS Press (1)
  5. International Scientific Literature, Inc. (1)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors
    Journal Article

    Chakraborty, G.; Khan Patail, N.; Hirani, R.; Nandakumar, S.; Mazzu, Y. Z.; Yoshikawa, Y.; Atiq, M.; Jehane, L. E.; Stopsack, K. H.; Lee, G. S. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
    Journal Article

    Mazzu, Y. Z.; Armenia, J.; Nandakumar, S.; Chakraborty, G.; Yoshikawa, Y.; Jehane, L. E.; Lee, G. S. M.; Atiq, M.; Khan, N.; Schultz, N.; more...
    Molecular Oncology (2020)

    Fulltext@MSK | Save
  • Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness
    Meeting Abstract

    Chakraborty, G.; Ghosh, A.; Nandakumar, S.; Armenia, J.; Mazzu, Y. Z.; Atiq, M. O.; Lee, G. S. M.; Mucci, L. A.; Merghoub, T.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression
    Journal Article

    Chakraborty, G.; Armenia, J.; Mazzu, Y. Z.; Nandakumar, S.; Stopsack, K. H.; Atiq, M. O.; Komura, K.; Jehane, L.; Hirani, R.; Chadalavada, K.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Targeting checkpoint kinases in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors
    Meeting Abstract

    Atiq, M. O.; Chakraborty, G.; Nandakumar, S.; Mazzu, Y. Z.; Stopsack, K. H.; Jehane, L. E.; Yoshikawa, Y.; Khan, N.; Lee, G. S. M.; Kantoff, P. W.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Combination treatment of PARP and SRC inhibitors in BRCA2 mutated prostate cancer
    Meeting Abstract

    Khan, N.; Chakraborty, G.; Nandakumar, S.; Mazzu, Y. Z.; Atiq, M.; Yoshikawa, Y.; Lee, G. S. M.; Kantoff, P.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Mechanisms of resistance to poly (ADP-ribose) polymerase inhibitors in prostate cancer
    Meeting Abstract

    Atiq, M.; Chakraborty, G.; Nandakumar, S.; Mazzu, Y. Z.; Stopsack, K.; Yoshikawa, Y.; Khan, N.; Lee, G. S. M.; Kantoff, P. W.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A comparative analysis of fraction genome altered vs tumor mutational count in prostate cancer
    Meeting Abstract

    Chakraborty, G.; Atiq, M.; Nandakumar, S.; Mazzu, Y. Z.; Armenia, J.; Yoshikawa, Y.; Khan, N.; Lee, G. S. M.; Mucci, L.; Kantoff, P. W.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A novel mechanism driving poor-prognosis prostate cancer: Overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2)
    Journal Article

    Mazzu, Y. Z.; Armenia, J.; Chakraborty, G.; Yoshikawa, Y.; Coggins, S. A.; Nandakumar, S.; Gerke, T. A.; Pomerantz, M. M.; Qiu, X.; Zhao, H.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression
    Meeting Abstract

    Mazzu, Y. Z.; Armenia, J.; Chakraborty, G.; Yoshikawa, Y.; Gerke, T. A.; Atiq, M. O.; Stopsack, K. H.; Komura, K.; Lee, G. S. M.; Mucci, L. A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save